Cyclobenzaprine — Centrally acting skeletal muscle relaxant. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Cyclobenzaprine
Class
Centrally acting skeletal muscle relaxant
Mechanism
Relieves skeletal muscle spasm of local origin without interfering with muscle function. Animal studies support a mainly central action rather than a direct action at skeletal muscle or the neuromuscular junction.
Used for
Short-term relief of muscle spasm from acute, painful musculoskeletal conditions, as an adjunct to rest and physical therapy
Serotonin syndrome; TCA-like cardiovascular / CNS effects; Not recommended in elderly or hepatic impairment; The selected extended-release capsule is intended only for short periods, up to 2–3 weeks; effectiveness for central spasticity has not been established
Interactions
MAO inhibitors; Alcohol, barbiturates, CNS depressants; Tramadol
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260901 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Not established; may be due to general CNS depression. No direct action on striated muscle, motor end plate or nerve fiber.
Only on the Methocarbamol card: Used for — Adjunct to rest, physical therapy and other measures for discomfort associated with acute painful musculoskeletal conditions · Common side effects — Drowsiness; Dizziness / lightheadedness; Nausea / vomiting; Headache; Blurred vision · Warnings — Hypersensitivity to methocarbamol; Alcohol and other CNS depressants can add to sedating effects; Mental or physical ability for driving and hazardous tasks may be impaired; Pregnancy use requires a clinician's benefit-risk assessment · Interactions — CNS depressants and alcohol; Pyridostigmine (myasthenia gravis)
Mechanism: Central alpha-2 adrenergic agonist presumed to reduce spasticity through increased presynaptic inhibition of motor neurons, with the greatest effects on polysynaptic pathways.
On both cards: Common side effects — Dry mouth; Dizziness; Somnolence
Only on the Tizanidine card: Used for — Spasticity · Common side effects — Asthenia; Urinary tract infection · Warnings — Hypotension; Liver injury; Sedation / hallucinations · Interactions — Fluvoxamine / ciprofloxacin (contraindicated); Other CYP1A2 inhibitors; Oral contraceptives
Mechanism: The precise mechanism is not fully known. Baclofen can inhibit monosynaptic and polysynaptic spinal reflexes, possibly by hyperpolarizing afferent terminals; supraspinal actions may also contribute.
On both cards: Common side effects — Dizziness; Fatigue
Only on the Baclofen card: Used for — Alleviation of reversible spasticity due to multiple sclerosis; May also be of value for patients with spinal cord injuries or other spinal cord diseases · Common side effects — Drowsiness; Weakness · Warnings — Abrupt withdrawal: hallucinations, seizures; Neonatal withdrawal if used in pregnancy; Not for rheumatic muscle spasm · Interactions — CNS depressants and alcohol
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera